Trial status: In Follow-Up
The MAGMA trial is a platform trial that will aim to assess a number of options in standard of care for the management of glioblastoma. Initial questions of interest are i) whether or not to give daily temozolomide as soon as possible after surgery prior to chemoradiotherapy (CRT) and ii) whether to give 6 cycles of temozolomide after CRT, or continue monthly treatment until disease progression.
NHMRC Clinical Trials Centre
Locked Bag 77
Camperdown
NSW, 1450
Australia
Email: magma.study@sydney.edu.au
Arm 1. Temozolomide before chemoradiotherapy: 75mg/m2 per day and will continue through radiotherapy. Cycle 1 will be given at 150mg/m2 and subsequent cycles at 200mg/m2 for days 1-5 of a 28 day cycle.
Control Arm 1: After surgery, start temozolomide at the same time as radiotherapy. Daily treatment at 75mg/m2 and will continue through radiotherapy.
Arm 2. Adjuvant Temozolomide after chemoradiotherapy until disease progression: Cycle 1 will be given at 150mg/m2 and subsequent cycles at 200mg/m2 for days 1-5 of a 28 day cycle.
Control Arm 2: After chemoradiotherapy, take adjuvant temozolomide for 6 cycles. Treatment will commence approximately 4 weeks following chemoradiotherapy. Cycle 1 will be given at 150mg/m2 and subsequent cycles at 200mg/m2 for days 1-5 of a 28 day cycle for a maximum of 6 cycles in total.
Multi-Arm GlioblastoMa Australasia (MAGMA): Protocol for a multiarm randomised clinical trial for people affected by glioblastoma.
Benjamin Y Kong, Hao-Wen Sim, Elizabeth H Barnes, Anna K Nowak, Elizabeth J Hovey, Rosalind Jeffree, Rosemary Harrup, Jonathon Parkinson, Hui K Gan, Mark B Pinkham,Sonia Yip, Merryn Hall, Emily Tu, Candace Carter, Eng-Siew Koh, Zarnie Lwin, Anthony Dowling,John S Simes, Craig Gedye BMJ Open 2022;12:e058107.
https://doi.org/10.1136/bmjopen-2021-058107
28 Participating Sites
338 Recruitment Target
NHMRC Clinical Trials Centre
Locked Bag 77
Camperdown
NSW, 1450
Australia
